title: [Analyses of karyotypic characteristics and prognosis in pediatric acute myeloblastic leukemia].
abstract: OBJECTIVE
  Acute myeloblastic leukemia (AML) accounts for 15 to 25 percent of childhood acute leukemias. Cytogenetic information is important for diagnosis, classification and prognosis of AML. Our aim was to analyze the relationship between karyotypic characteristics and prognosis of childhood AML.
  
  
  METHODS
  According to karyotypic characteristics, 128 newly diagnosed children AML were separated into 4 subgroups: patients with t(15;17) (group APL), patients with t(8;21)/inv(16) (group A), patients with -7/t(9;22)/complex karyotypes (group C) and the others (group B). Prognoses of these patients were analyzed.
  
  
  RESULTS
  The ages ranged from 1 to 16 years with the mean age of 7 years. 85 boys and 43 girls were included in this study. The 4-year event-free survival (EFS) and overall survival (OS) rates were (55.9 ± 4.7)% and (69.3% ± 4.5)%, respectively. The 4-year EFS and OS of non-M(3)-AML patients were (49.9 ± 5.2)% and (57.1 ± 6.0)%, respectively. The probabilities of 4-year EFS of the four subgroups were (72.2 ± 1.1)%, (66.3 ± 7.7)%, (38.5 ± 9.1)% and (20.1 ± 12.3)%, respectively (P = 0.000). The probabilities of 4-year OS were (92.6 ± 5.1)%, (69.4 ± 7.9)%, (55.6 ± 8.6)% and (30.0 ± 12.3)%, respectively (P = 0.000).
  
  
  CONCLUSIONS
  Cytogenetic aberrations seen in pediatric AML had a significant impact on prognosis.
authors: Institute of Hematology and Blood Disease Hospital, CAMS & PUMC, Tianjin, China.
authors: Min
authors: M
authors: Ruan
authors: Ya-Qin
authors: YQ
authors: Wang
authors: Li
authors: L
authors: Zhang
authors: Yao
authors: Y
authors: Zou
authors: Xiao-Fan
authors: XF
authors: Zhu
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D025063:Chromosome Disorders / Q000235:genetics; D005260:Female; D006801:Humans; D007223:Infant; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D011379:Prognosis; D016896:Treatment Outcome